@article{3219733,
    title = "Histone Deacetylase (HDAC) Inhibitors: A Promising Weapon to Tackle Therapy Resistance in Melanoma",
    author = "Palamaris, K. and Moutafi, M. and Gakiopoulou, H. and Theocharis, S.",
    journal = "International Journal of Molecular Sciences",
    year = "2022",
    volume = "23",
    number = "7",
    publisher = "MDPI",
    issn = "1422-0067",
    doi = "10.3390/ijms23073660",
    keywords = "histone deacetylase;  histone deacetylase inhibitor, human;  melanoma;  pathology, Histone Deacetylase Inhibitors;  Histone Deacetylases;  Humans;  Melanoma",
    abstract = "Melanoma is an aggressive malignant tumor, arising more commonly on the skin, while it can also occur on mucosal surfaces and the uveal tract of the eye. In the context of the unresectable and metastatic cases that account for the vast majority of melanoma-related deaths, the currently available therapeutic options are of limited value. The exponentially increasing knowledge in the field of molecular biology has identified epigenetic reprogramming and more specifically histone deacetylation (HDAC), as a crucial regulator of melanoma progression and as a key driver in the emergence of drug resistance. A variety of HDAC inhibitors (HDACi) have been developed and evaluated in multiple solid and hematologic malignancies, showing promising results. In melanoma, various experimental models have elucidated a critical role of histone deacetylases in disease patho-genesis. They could, therefore, represent a promising novel therapeutic approach for advanced disease. A number of clinical trials assessing the efficacy of HDACi have already been completed, while a few more are in progress. Despite some early promising signs, a lot of work is required in the field of clinical studies, and larger patient cohorts are needed in order for more valid conclusions to be extracted, regarding the potential of HDACi as mainstream treatment options for melanoma. © 2022 by the authors. Licensee MDPI, Basel, Switzerland."
}